Accuray Incorporated (ARAY) stock forecast & analysis
0.2998
NasdaqCM · USD
Up: +0.0847, +39.4%
1 analysis
- Open
- 0.2877
- Previous close
- 0.2151
- Day range
- 0.2840 – 0.3820
- 52-week range
- 0.2200 – 2.10
- Volume (shares)
- 374.78M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 119.44M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.39
- Market cap
- 35.81M
Market Scanner’s AI analysis of Accuray Incorporated (ARAY), updated September 2026: Accuray's CyberKnife platform enhancements and strategic partnerships were central to recent analyses, alongside revenue declines and technical indicators.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Accuray Incorporated (ARAY) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Accuray's CyberKnife platform enhancements and strategic partnerships were central to recent analyses, alongside revenue declines and technical indicators.
Recent analyses examined Accuray Incorporated's (ARAY) strategic partnerships with Samsung NeuroLogica and RaySearch, aimed at enhancing its CyberKnife platform and adaptive radiation therapy capabilities. The reports also covered a notable year-over-year quarterly revenue decrease and a negative profit margin on a TTM basis. Market data indicated a strong short-term upward trend with positive momentum, though the long-term trend remained bearish relative to the 200-day SMA.
ARAY news & sentiment
News reports highlighted Accuray's strategic partnerships aimed at enhancing its radiation therapy platforms, alongside a significant collaboration for advanced imaging. Social media discussion was not covered in the provided notes.
ARAY technical picture
ARAY's price action showed a strong recent upward trend, with the current price exceeding both the 10-day EMA and 50-day SMA. Momentum indicators like RSI and MFI suggested strong buying pressure, though the price remained below the 200-day SMA, indicating a bearish long-term trend.
Fundamentals
Accuray Incorporated (ARAY) reported a year-over-year quarterly revenue decrease and a net loss for fiscal year 2026. The company's TTM profit and operating margins were negative.
Factors discussed — upside
- Strong 7-day price change of +25.0% and sustained positive momentum over 30 and 91 days.
- Current price above 10-day EMA and 50-day SMA, indicating short-term and medium-term strength.
- RSI at 63.73 indicating strong buying pressure.
- MFI at 98.98 suggesting significant buying pressure.
- Partnership with Samsung NeuroLogica to enhance CyberKnife imaging capabilities.
Factors discussed — risks
- Year-over-year quarterly revenue growth was -20.9%.
- Negative profit margin of -12.2% and negative operating margin of -3.3% on a TTM basis.
- Net income for fiscal year 2026 was a loss of $49.19 million.
- Price significantly below the 200-day SMA of 0.45, indicating a bearish long-term trend.
- Strategic Partnerships
- Revenue Trends
- Technical Indicators
- Profitability
Summary updated .
ARAY technical indicators
Common technical indicators for ARAY, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.26 | Price above |
| 10-day exponential moving average | 0.24 | Price above |
| Relative strength index (14-day) | 63.73 | Neutral |
| MACD line (12/26/9) | -0.0065 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.21 – 0.29 | Price above the upper band |
Analyses
Recent ARAY.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Accuray Incorporated?
- Recent analyses highlighted Accuray's strategic partnerships with Samsung NeuroLogica and RaySearch, aimed at enhancing its CyberKnife platform and adaptive radiation therapy capabilities. Market data indicated a strong short-term upward trend with positive momentum, supported by a significant 7-day price change and current price levels above key moving averages.
- What are the risks for Accuray Incorporated?
- The reports noted a year-over-year quarterly revenue decrease of 20.9% and a negative profit margin of -12.2% on a TTM basis, with fiscal year 2026 reporting a substantial net loss. The stock's price remained significantly below its 200-day SMA, suggesting a bearish long-term trend.
- Is Accuray Incorporated bullish or bearish?
- Recent AI analyses of Accuray Incorporated examined factors on both sides. Discussed upside: Recent analyses highlighted Accuray's strategic partnerships with Samsung NeuroLogica and RaySearch, aimed at enhancing its CyberKnife platform and adaptive radiation therapy capabilities. Market data indicated a strong short-term upward trend with positive momentum, supported by a significant 7-day price change and current price levels above key moving averages. Discussed risks: The reports noted a year-over-year quarterly revenue decrease of 20.9% and a negative profit margin of -12.2% on a TTM basis, with fiscal year 2026 reporting a substantial net loss. The stock's price remained significantly below its 200-day SMA, suggesting a bearish long-term trend. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Accuray Incorporated?
- News reports highlighted Accuray's strategic partnerships aimed at enhancing its radiation therapy platforms, alongside a significant collaboration for advanced imaging. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Accuray Incorporated?
- Every analysis of Accuray Incorporated runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh ARAY.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.